Apalutamide Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 60mg
Reference Brands: ERLEADA (USA/EU)
Category:
Oncology Cancer Care
Apalutamide is a next-generation androgen receptor inhibitor used for the treatment of prostate cancer, including non-metastatic castration-resistant and metastatic castration-sensitive forms. It works by blocking the effects of androgens, hormones that promote the growth of prostate cancer cells. Administered orally, Apalutamide is often used in combination with androgen deprivation therapy (ADT). Erleada has become an important option in prolonging survival and delaying disease progression in prostate cancer patients.
Apalutamide is available in Tablets
and strengths such as 60mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Apalutamide is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Apalutamide can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing